Company news
Mind Cure Health Inc news in 2021
Mind Cure Health Inc's news releases, calls and decks from 2021, newest first.
MINDCURE Announces Certification of HIPAA Compliance, Bringing iSTRYM Closer to Commercial Deployment in the Second Quarter of 2022
December 16, 2021
MINDCURE Appoints Dr. Doron Sagman as Chief Medical Officer
December 14, 2021
MINDCURE to Participate in Upcoming Conferences in December 2021
December 2, 2021
MINDCURE Provides Update on Studies and Clinical Trials
November 4, 2021
MINDCURE Signs LOI with Awakn Life Sciences to Distribute Ketamine Protocol for Alcohol Use Disorder into Clinics Across United States and Canada through iSTRYM, MINDCURE's Digital Therapeutics Platform
October 28, 2021
MINDCURE Announces Participation at Upcoming Events in November 2021
October 27, 2021
MINDCURE Announces Financial Results for the First Quarter of Fiscal 2022
October 26, 2021
MINDCURE to Webcast Live at the KCSA Psychedelics Virtual Investor Conference on October 13, 2021
October 7, 2021
MINDCURE Announces Commencement of Trading on the OTCQX Best Market
September 30, 2021
MINDCURE Announces Financial Results for Fiscal 2021
August 31, 2021
MINDCURE Welcomes Dr. Ken Weingardt, Digital Therapy Visionary, as a Senior Clinical Technology Advisor to its Psychedelic Digital Therapeutics Team
August 10, 2021
MINDCURE Appoints Jerry White, Award-Winning Humanitarian Activist Who Shares in the 1997 Nobel Peace Prize, as Company Advisor
August 4, 2021
MINDCURE Launches Second Stage of Manufacturing Synthetic Ibogaine for Use in Psychedelic Clinical Research
July 27, 2021
MINDCURE Announces Filing of U.S. Provisional Patent Applications for Company's First Fully Synthetic Routes to Create an Ibogaine Psychedelic Compound
July 13, 2021
MINDCURE Adopts Advance Notice Policy
July 12, 2021
Maxim Group Initiates Coverage of Mind Cure Health
June 30, 2021
MINDCURE Develops Proprietary Ketamine-Enhanced Psychotherapy Protocols for Treatment of Pain and Depression
June 17, 2021
MINDCURE Successfully Completes First Stage of Manufacturing Synthetic Ibogaine for Use in Psychedelic Clinical Research
June 3, 2021
Dr. Joel Raskin, a leader in psychiatry and neuroscience drug development, joins MINDCURE as Chief Medical Officer
May 20, 2021
MINDCURE Appoints Dr. John Brownstein, the Chief Innovation Officer at Boston Children's Hospital, as Company Advisor
May 19, 2021
MINDCURE Shares Update on Strong Financial Position, Near Term Revenue Drivers and Timeline for iSTRYM's Market Launch, Delivering Mental Wealth
April 29, 2021
MINDCURE Announces Partnership with SOMA Breath Inc. to License its Breathwork Program and Develop Custom Breathwork for Psychedelic-Assisted Psychotherapies within iSTRYM
April 27, 2021
MINDCURE Announces Experienced Finance Executive Michael Wolfe as CFO and appoints Larissa Chaikowsky to its Board of Directors
April 22, 2021
MINDCURE Partners its iSTRYM Technology with LUCID to Discover and Create Proprietary Music Experiences for Use During Psychedelic-Assisted Therapy Sessions
April 21, 2021
MINDCURE Announces The Addition of Daniel Herrera, A Pharmaceutical Industry Executive With Specific Experience in Medical Psychoactive Segment
April 14, 2021
MINDCURE Announces Partnership with Speak Ai to Enhance iSTRYM, the Company's Psychedelic Digital Therapeutics Technology Platform
April 13, 2021
MINDCURE Announces Additional Equity Investment in ATMA, The First Government Approved Psychedelic Journey Centers In Canada; MCUR President and CEO, Kelsey Ramsden Named to ATMA Board of Directors
April 8, 2021
MINDCURE Files Provisional Patent Application For iSTRYM, its Proprietary AI Digital Therapeutics (DTx) SaaS Platform, Designed To Enhance Effectiveness Of Psychedelic-Assisted Therapies For Practitioners And Patients
March 31, 2021
March Psychedelic Capital Investigates Ethical IP and Financial Instruments
March 30, 2021
Ty Tashiro joins MINDCURE as the Senior Translational and Psychometric Architect for iSTRYM's AI-Driven Psychedelic Digital Therapeutic Technology
March 19, 2021
MINDCURE Names Tarik Lebbadi as Chief Operating Officer
March 15, 2021
MINDCURE Receives Unconditional Ethics Approval for its Psychedelic Integration Protocol Research Study
March 9, 2021
MINDCURE Discovers Potential Opportunity for Ibogaine-Assisted Psychotherapy to Treat Neuropathic Pain and Traumatic Brain Injury
March 4, 2021
MINDCURE Announces Manufacturing of Synthetic Ibogaine to be Used in Company's Clinical Research
March 3, 2021
MINDCURE Completes Its Initial Strategic Equity Investment in ATMA, Canada's First Commercial Provider of Legal, Psychedelic-Assisted, Therapy Utilizing Psilocybin
March 2, 2021
Mind Cure Announces Addition of Global Technology Leader Robert C. Hill to Board of Directors
February 22, 2021
MINDCURE Announces Official Release of Nootropic and Adaptogen Products, Available on E-Commerce Platform
February 18, 2021
Mind Cure Comments on Recent Promotional Activity
February 17, 2021
Mind Cure Engages Dr. Dan Engle as Primary Investigator for Research in Traumatic Brain Injury with Psychedelics
February 17, 2021
MINDCURE's Proprietary Bioinformatics Platform, PsyCollage, Beta Tested and Deployed for Product Discovery and Lead Optimization
February 16, 2021
MINDCURE Announces Listing of Warrants
February 11, 2021
Mind Cure Announces Closing of $23 Million Bought Deal Offering Including Full Exercise of Over-Allotment Option
February 10, 2021
MINDCURE Announces Pre- and Post-Psychedelic Therapy Adaptogen Supplements, Defining New Product Category
January 26, 2021
Mind Cure Health Inc. Announces an Increase to Previously Announced Bought Deal Public Offering
January 22, 2021
Mind Cure Health Inc. Announces an Increase to Previously Announced Bought Deal Public Offering
January 22, 2021
Mind Cure Health Inc. Announces $10 Million Bought Deal Public Offering
January 21, 2021
MINDCURE Included in First Psychedelic ETF & North American Psychedelics Index
January 21, 2021
Mind Cure Signs LOI to Acquire an Ownership Interest in Psychedelic Treatment Center ATMA, Selected by Section 56 Exempt Patient for Psilocybin Therapy
January 12, 2021
Mind Cure Announces Build-Out of Digital Therapeutics, iSTRYM: A Technology Platform for Mental Wellness Optimization & Psychedelic Research
January 6, 2021